A systematic review on the quality, validity and usefulness of current cost-effectiveness studies for treatments of neovascular age-related macular degeneration

Mari Elshout*, Carroll A. B. Webers, Margriet I. van der Reis, Jan S. A. G. Schouten

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)770-778
Number of pages9
JournalActa Ophthalmologica
Volume96
Issue number8
DOIs
Publication statusPublished - Dec 2018

Keywords

  • aflibercept
  • bevacizumab
  • cost-effectiveness
  • exudative age-related macular degeneration
  • photodynamic therapy
  • ranibizumab
  • VERTEPORFIN PHOTODYNAMIC THERAPY
  • UTILITY ANALYSIS
  • CONTRAST SENSITIVITY
  • OF-LIFE
  • CHOROIDAL NEOVASCULARIZATION
  • LASER PHOTOCOAGULATION
  • RANIBIZUMAB LUCENTIS
  • PEGAPTANIB SODIUM
  • VISUAL-ACUITY
  • BEVACIZUMAB

Cite this